Alzheimer's disease and oxidative stress: Implications for novel therapeutic approaches

Progress in Neurobiology

Volumn 57, Issue 3, 1999, Pages 301-323

  Behl, Christian ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ESTROGEN;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CELL PROTECTION; CYTOTOXICITY; DRUG TARGETING; HISTOPATHOLOGY; HUMAN; NERVE CELL NECROSIS; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0032890439     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(98)00055-0     Document Type: Review

References (293)

1. Abraham C. R., Selkoe D. J., Potter H. Immunochemical identification of the serine protease inhibitor alpha-a-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell. 52:1988;487-501.
2. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Z. Psychiatrie Psychisch-Gerichtlichen Medizin. 64:1907;146-148.
3. Aguzzi A., Brandner S., Marino S., Steinbach J. P. Transgenic and knockout mice in the study of neurodegenerative diseases. J. Mol. Med. 74:1996;111-126.
4. Aisen P. S. Inflammation and Alzheimer disaease. Mol. Chem. Neuropathol. 28:1996;83-88.
5. Aisen P. S., Davis K. L. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am. J. Psychiatry. 151:1994;1105-1113.
6. Aisen P. S., Pasinetti G. M. Glucocorticoids in Alzheimers-disease - the story so far. Drugs and Aging. 12:1998;1-6.
7. Akiyama H., McGeer P. L. Brain microglia constitutively express β-2 integrins. J. Neuroimmunol. 30:1990;81-93.
8. Ames B. N., Shigenaga M. K., Hagen T. M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. natl Acad. Sci. U.S.A. 90:1993;7915-7922.
9. Aronson M. K., Ooi W. L., Morgenstern H., Hafner A., Masur D., Crystal H., Frishman W. H., Fisher D., Katzman R. Women, myocardial infarction, and dementia in the very old. Behav. Neural Biol. 40:1990;1102-1106.
10. Aust S. D., Morehouse L. A., Thomas C. E. Role of metals in oxygen radical reactions. J. Free Radic. Biol. Med. 1:1985;3-25.
11. Baeuerle P. A., Henkel T. Function and activation of NF-kappa B in the immune system. A. Rev. Immun. 12:1994;141-179.
12. Baichwal V. R., Baeuerle P. A. Apoptosis: activate NF-κB or die? Current Biol. 7:1997;94-96.
13. Balazs L., Leon M. Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem. Res. 19:1994;1131-1137.
14. Beal M. F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38:1995;357-366.
15. Beckman J. S., Koppenol W. H. Nitric oxide, superoxide, and peroxynitrite-the good, the bad, and the ugly. Am. J. Physiol. 40:1996;C1424-C1437.
16. Beckman J. S., Chen J., Crow J. P., Ye Y. Z. Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration. Prog. Brain Res. 103:1994;371-380.
17. Behl C. Amyloid β-protein toxicity and oxidative stress in Alzheimer's disease. Cell Tissue Res. 290:1997;471-480.
18. Behl C., Davis J., Cole G. M., Schubert D. Vitamin E protects nerve cells from amyloid β protein toxicity. Biochem. Biophys. Res. Commun. 186:1992;944-952.
19. Behl C., Davis J. B., Klier F. G., Schubert D. Amyloid β peptide induces necrosis rather than apoptosis. Brain Res. 645:1994;253-264.
20. Behl C., Davis J. B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell. 77:1994;817-822.
21. Behl C., Widmann M., Trapp T., Holsboer F. 17-β Estradiol protects from oxidative stress-induced cell death in vitro. Biochem. Biophys. Res. Commun. 216:1995;473-482.
22. Behl, C., Trapp, T., Skutella, T. and Holsboer, F. (1997a) Protection against oxidative stress-induced neuronal cell death-a novel role for RU486. Eur. J. Neurosci. 912-920.
23. Behl, C., Skutella, T., Lezoualc'h, F., Post, A., Widmann, M., Newton, C. and Holsboer, F. (1997b) Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol. Pharm. 535-541.
24. Blass J. P. Pathophysiology of the Alzheimer syndrome. Neurology. 43:1993;25-38.
25. Braak H., Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1:1991;213-216.
26. Brandner S., Isenmann S., Raeber A., Fischer M., Sailer A., Kobayashi Y., Marino S., Weissmann C., Aguzzi A. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature. 379:1996;339-343.
27. Braughler J. M., Hall E. D., Jacobson E. J., McCall J. M., Means E. D. The 21-aminosteroids: potent inhibitors of lipid peroxidation for the treatment of central nervous system trauma and ischemia. Drugs of the Future. 14:1989;143-151.
28. Breitner J. C. S. The role of antiinflammatory drugs in the prevention and treatment of Alzheimer's disease. A. Rev. Med. 47:1996;401-411.
29. Breitner J. C. S., Gau B. A., Welsh K. A., Plassman B. L., McDonald W. M., Helms M. J., Anthony J. C. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 44:1992;227-232.
30. Breitner J. C. S., Welsh K. A., Helms M. J., Gaskell P. C., Gau B., Roses A. D., Pericak-Vance M. A., Saunders A. M. Delayed onset of Alzheimer's disease with non-steroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol. Aging. 16:1995;523-530.
31. Brown R. H. Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice. Cell. 80:1995;687-692.
32. Brun A., Gustafson L. Distribution of cerebral degeneration in Alzheimer's disease. Arch. Psychiatr. Nervenkr. 22:1976;15-33.
33. Brun A., Gustafson L. Limbic lobe involvement in presenile dementia. Arch. Psychiatr. Nervenkr. 226:1978;79-93.
34. Busciglio J., Gabuzda D. H., Matsudaira P., Yankner B. A. Generation of β-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc. natl Acad. Sci. U.S.A. 90:1993;2092-2096.
35. Butterfield D., Hensley K., Harris M., Mattson M., Carney J. β-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochem. Biophys. Res. Commun. 200:1994;710-715.
36. Cai X., Golde T., Younkin S. Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science. 259:1993;514-516.
37. Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A., Seubert P., Vigo-Pelfrey C., Lieberburg I., Selkoe D. Mutation of the β-protein production. Nature. 360:1992;672-674.
38. Citron M., Vigo-Pelfrey C., Teplow D. B., Miller C., Schenk D., Johnston J., Winblad B., Venizelos N., Lann-Felt L., Selkoe D. J. Excessive production of amyloid β-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer diesease mutation. Proc. natl Acad. Sci. U.S.A. 91:1994;11993-11997.
39. Citron M., Westaway D., Xia W.et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nature Med. 3:1997;67-72.
40. Clemens J. A., Panetta J. A. Neuroprotection by antioxidants in models of global and focal ischemia. Ann. N.Y. Acad. Sci. 738:1994;250-256.
41. Clemens J. A., Stephenson A. M. Implants containing beta-amyloid protein are not neurotoxic to young and old rat brain. Neurobiol. Aging. 13:1992;581-586.
42. Colton C. A., Snell J., Chernyshev O., Gilbert D. L. Induction of superoxide anion and nitric oxide production in cultured microglia. Ann. N.Y. Acad. Sci. 78:1994;54-63.
43. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., Pericak-Vance M. A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease late-onset families. Science. 261:1993;921-923.
44. Corder E. H., Saunders A. M., Risch N. J., Strittmatter W. J., Schmechel D. E., Gaskell J. P. C., Rimmler J. B., Locke P. A., Conneally P. M., Schmader K. E., Small G. W., Roses A. D., Haines J. L., Pericak-Vance M. A. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genetics. 7:1994;180-183.
45. Cotman C. W., Anderson A. J. A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol. Neurobiol. 10:1995;19-45.
46. Coyle J. T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
47. Cross A. R., Jones O. T. G. Enzymatic mechanisms of superoxide production. Biochim. Biophys. Acta. 1057:1991;281-298.
48. Dalcanto M. C. Comparison of pathological alterations in ALS and a murine transgenic model-pathogenetic implications. Clin. Neurosci. 3:1996;332-337.
49. Davies P., Duyckaerts C., Beyreuther K., Masters C. L., Peitte F., Hauw J. J. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunohistochemistry compared with conventional neuropathological techniques. Neurology. 38:1988;1688-1693.
50. Davis J. B., McMurray H. F., Schubert D. The amyloid beta-protein of Alzheimer's disease is chemotoctic for mononuclear phagocytes. Biochem. Biophys. Res. Commun. 189:1992;1096-1100.
51. Davis, P. (1994) Neuronal abnormalities, not amyloid, are the cause of dementia in Alzheimer disease. In: Alzheimer Disease, pp. 327-333. Eds R. D. Terry, R. Katzman and K. L. Bick. Raven Press, New York.
52. Davis R. E., Emmerling M. R., Jaen J. C., Moos W. H., Spiegel K. Therapeutic intervention in dementia. Critical Rev. Neurobio. 7:1993;41-83.
53. Delaere P., Duyckaerts C., Beyreuther K., Masters C. L., Peitte F., Hauw J. J. Large amounts of neocortical βA4 deposits without neuritic plaques or tangles in a psychometrically assessed nondemented case. Neurosci. Lett. 116:1990;87-93.
54. Duff K., Eckman C., Zehr C.et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature. 383:1996;710-713.
55. Dyrks T., Dyrks E., Hartmann T., Masters C., Beyreuther K. Amyloidogenicity of β/A4 and β/A4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J. Biol. Chem. 267:1992;18210-18217.
56. Eanes E. D., Glenner G. G. X-ray diffraction studies on amyloid filaments. J. Histochem. Cytochem. 16:1968;673-677.
57. Ebadi M., Srinivasan S. K., Baxi M. D. Oxidative stress and antioxidant therapy in Parkinson's disease. Progr. Neurobiol. 48:1996;1-19.
58. Eikelenboom P., Stam F. C. Immunoglobulins and complement factors in senile plaques. An immunohistochemical study. Acta Neurropath. 57:1982;239-242.
59. Eikelenboom P., Veerhuis T. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol. Aging. 17:1996;673-680.
60. Esch F., Keim P., Beattie E., Blacher R., Culwell A., Oltersdorf T., McClure D., Ward P. Cleavage of amyloid β peptide during constitutive processing of its precursor. Science. 248:1990;1122-1124.
61. Esler W. P., Stimson E. R., Ghilardi J. R., Felix A. M., Lu Y. A., Vinter H. V., Mantyh P. W., Maggio J. E. A-beta deposition inhibitor screen using synthetic amyloid. Nat. Biotechnol. 15:1997;258-263.
62. Evans D. A., Funkenstein H. H., Albert M. S., Scherr P. A., Cook N. R., Chown M. J., Hebert L. E., Hennekens C. H., Taylor J. O. Prevalence of Alzheimer's disease in a community population of older persons. J. Am. Med. Assoc. 262:1989;2551-2556.
63. Fernandez C. I., Gonzalez O., Soto J., Alvarez L., Quijano Z. Effects of chronic infusion of nerve growth factor (NGF) in AF64A-lesioned rats. Mol. Chem. Neuropathol. 28:1996;175-179.
64. Frautschy S. A., Baird A., Cole G. M. Effects of injected Alzheimer β-amyloid cores in rat brain. Proc. natl Acad. Sci. U.S.A. 88:1991;8362-8366.
65. Fridovich I. The biology of oxygen radicals. Science. 201:1978;875-880.
66. Fridovich I. Superoxide dismutase. An adaption to a paramagnetic gas. J. Biol. Chem. 264:1989;7761-7764.
67. Friedlich A. L., Butcher L. L. Involvement of free oxygen radicals in beta-amyloidoses: an hypothesis. Neurobiol. Aging. 15:1994;443-455.
68. Fröhlich L., Riederer P. Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. Arzneimittelforschung. 45:1995;443-446.
69. Games D., Khan K. M., Soriano F. G., Keim P. S., Davis P. L., Bryant K., Lieberburg I. Lack of Alzheimer pathology after beta-amyloid protein injections in rat brain. Neurobiol. Aging. 13:1992;569-576.
70. Games D., Adams D., Alessandri R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagopian S., Johnson-Wood K., Khan K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., McConlogue L., Montoya-Zavala M., Mucke L., Paganini L., Penniman E., Power M., Schenk D. B., Seubert P., Snyder B., Soriano F., Tan H., Vitale J., Wadsworth S., Wolozin B., Zhao J. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 373:1995;523-527.
71. Garnier M., Di Lorenzo D., Albertini A., Maggi A. Identification of estrogen-responsive genes in neuroblastoma SK-ER3 cells. J. Neurosci. 17:1997;4591-4599.
72. Giaccone G., Pedrotti B., Migheli A., Verga L., Perez J., Racagni G., Smith M. A., Perry G., De Gioia L., Selvaggini C., Salmona M., Ghiso J., Frangione B., Islam K., Bugiani O., Tagliavini F. Beta PP and Tau interaction. A possible link between amyloid and neurofibrillary tangles in Alzheimer's disease. American Journal of Pathology. 148:1996;79-87.
73. Giovanelli L., Casamenti F., Scali C., Bartolini L., Pepeu G. Differential effects of amyloid peptides β-(1-40) and β-(25-35) injections into the rat nucleus basalis. Neuroscience. 66:1995;781-792.
74. Glenner G. G. Alzheimer's disease: its proteins and genes. Cell. 52:1988;307-308.
75. Glenner G. G., Wong C. W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120:1984;885-890.
76. Goate A., Chartier-Harlin M., Mullan M.et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 349:1991;704-706.
77. Good P. F., Werner P., Hsu A., Olanow C. W., Perl D. P. Evidence of neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol. 149:1996;21-28.
78. Goodman Y., Mattson M. P. Secreted forms of β-amyloid precursor protein protect hippocampal neurons against amyloid β-peptide-induced oxidative injury. Exp. Neurol. 128:1994;1-12.
79. Goodman Y., Steiner M., Steiner S., Mattson M. P. Nordihydroguaiaretic acid protects hippocampal neurons against amyloid β-peptide toxicity, and attenuates free radical and calcium accumulation. Brain Res. 654:1994;171-176.
80. Green P. S., Bishop J., Simpkins J. W. 17α-Estradiol exerts neuroprotective effects on SK-N-SH cells. J. Neurosci. 17:1997;511-515.
81. Greenberg S., Koo E., Selkoe D., Qiu W., Kosik K. Secreted β-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. Proc. natl Acad. Sci. U.S.A. 91:1994;7104-7108.
82. Griffin W. S. T., Stanley L. C., Ling C., White L., MacLeod V., Perror L. J., White Iii C. L., Araoz C. Brain interleukin 1 and S-100 immunorecativity are elevated in Down syndrome and Alzheimer disease. Proc. natl Acad. Sci. U.S.A. 86:1989;7611-7615.
83. Grilli M., Pizzi M., Memo M., Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science. 274:1996;1383-1385.
84. Gsell W., Conrad R., Hickethier M., Sofic E., Fröhlich L., Wichart I., Jellinger K., Moll G., Rasmayr G., Beckmann H., Riederer P. Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J. Neurochem. 64:1995;1216-1223.
85. Gustafsson J. A. Estrogen receptor beta-getting in on the action. Nat. Med. 3:1997;493-494.
86. Gutteridge J. M. Hydroxyl radicals, iron, oxidative stress, and neurodegeneration. Ann. N.Y. Acad. Sci. 738:1994;201-213.
87. Haas C. Presenile because of presenilin-the presenilin genes and early onset Alzheimer's disease. Curr. Opin. Neurol. 9:1996;254-259.
88. Haass C. Presenilins: genes for life and death. Neuron. 18:1997;687-690.
89. Haass C., Selkoe D. J. Cellular processing of β-amyloid precursor protein and the genesis of amylod β-peptide. Cell. 75:1993;1039-1042.
90. Haass C., Hung A., Selkoe D., Teplow D. Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid β-protein precursor. J. Biol. Chem. 269:1992;17741-17748.
91. Haass C., Hung A. Y., Citron M., Teplow D. B., Selkoe D. J. Beta-amyloid, protein processing and Alzheimer's disease. Arzneimittel-Forschung/Drug Res. 45-1:1995;398-402.
92. Haga S., Akai K., Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. Acta Neuropathol. 77:1989;569-575.
93. Hall E. D., Braughler J. M. Central nervous system trauma and stroke. II. Physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation. Free Radic. Biol. Med. 6:1989;303-313.
94. Halliwell, B. and Gutteridge, J. M. C. (1989) Free Radicals in Biology and Medicine, 2nd edn. Oxford University Press, Oxford.
95. Halliwell B., Gutteridge J. M. C., Cross C. E. Free radicals, antioxidants, and human disease: where are we now? J. Lab. Clin. Med. 119:1992;598-620.
96. Hajimohammadreza I., Brammer M. Brain membrane fluidity and lipid peroxidation in Alzheimer's disease. Neurosci. Lett. 112:1990;333-337.
97. Hardy J., Allsop D. Amyloid deposition as the central event in the etiology of Alzheimer's disease. Trends Pharmac. Sci. 12:1991;383-388.
98. Hardy J. New insights into the genetics of Alzheimer's disease. Ann. Med. 28:1996;255-258.
99. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20:1997;154-159.
100. Harman D., Eddy D. E., Noffsinger J. Free radical theory of aging: inhibition of amyloidosis in mice by antioxidants; possible mechanism. J. Am. Geriatr. Soc. 24:1976;203-210.
101. Harper J. D., Lansbury P. T. Models of amyloid seeding in Alzheimer's disease and scrapie-mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. A. Rev. Biochem. 66:1997;385-407.
102. Harris M. E., Hensley K., Butterfield A., Leedle R. A., Carney J. M. Direct evidence of oxidative injury produced by the Alzheimer's β-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 131:1995;193-202.
103. Henderson V. W., Paganini-Hill A., Emanuel C. K., Dunn M. E., Buckwalter J. G. Estrogen replacement therapy in older women. Arch. Neurol. 51:1994;896-900.
104. Hensley K., Carney J. M., Mattson M. P., Aksenova M., Harris M., Wu J. F., Floyd R. A., Butterfield D. A. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. natl Acad. Sci. U.S.A. 91:1994;3270-3274.
105. Higgins L. S., Holtzman D. M., Rabin J., Mobley W. C., Cordell B. Transgenic mouse brain histopathology resembles early Alzheimer's disease. Ann. Neurol. 35:1994;598-607.
106. Holcomb L., Gordon M. N., McGowan E.et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med. 4:1998;97-100.
107. Honjo H., Tanak K., Kashiwagi T., Urabe M., Okada H., Hayashi M., Hayashi K. Senile dementia-Alzheimer's type and estrogen. Horm. Metab. Res. 27:1995;204-207.
108. Hoyer S. Age as a risk factor for sporadic dementia of the Alzheimer type? Ann. N.Y. Acad. Sci. 719:1994;248-256.
109. Hoyer S., Henneberg N., Knapp S., Lannert H., Martin E. Brain glucose metabolism is controlled by amplification and desensitization of the neuronal insulin receptor. Ann. N.Y. Acad. Sci. 777:1996;374-379.
110. Hsiao K., Borchelt D. R., Olson K., Johannsddlir R., Kitt C., Yunis W., Xu S., Eckman C., Younkin S., Price D. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron. 15:1995;1203-1218.
111. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-103.
112. Hutton M., Hardy J. The presenilins and Alzheimer's disease. Hum. Mol. Genetics. 6:1997;1639-1646.
113. Hyman B. T., van Hoesen G. W., Damasio A. R. Memory-related neural systems in Alzheimer's disease: an anatomic study. Neurology. 40:1990;1721-1730.
114. Iversen L. L., Mortishire-Smith R. J., Pollack S. J., Shearman M. S. The toxicity in vitro of β-amyloid protein. Biochem. J. 311:1995;1-16.
115. Iwasaki K., Sunderland T., Kusiak J. W., Wolozin B. Changes in gene transcription during a beta-mediated cell death. Mol. Psychiat. 1:1996;65-71.
116. Jaffe A. B., Toran-Allerand C. D., Greengard P., Gandy S. E. Estrogen regulates metablism of Alzheimer amyloid beta precursor protein. J. Biol. Chem. 269:1994;13065-13068.
117. Jouzeau J. Y., Terlain B., Abid A., Nedelec E., Netter P. Cyclo-oxygenase isoenzymes-How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs. 53:1997;563-582.
118. Kaltschmidt B., Bäuerle P. A., Kaltschmidt C. Potential involvement of the transcription factor NF-κB in neurological disorders. Mol. Aspects Med. 14:1993;171-190.
119. Kaltschmidt B., Uherek M., Volk B., Baeuerle P., Kaltschmidt C. Transcription factor NF-κB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc. natl Acad. Sci. U.S.A. 94:1997;2642-2647.
120. Kang J., Lemaire H. G., Unterbeck A., Salbaum J. M., Masters C. L., Grzeschik K. H., Multhaupt G., Beyreuther K., Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 325:1987;733-736.
121. Khachaturian Z. S. Diagnosis of Alzheimer's disease. Arch. Neurol. 42:1985;1097-1105.
122. Kida E., Wisniewski K. E., Wisniewski H. M. Early amyloid-β deposits show different immunoreactivity to the amino- and carboxyl-terminal regions of β-peptide in Alzheimer's disease and Down's syndrome brain. Neurosci. Lett. 193:1995;105-108.
123. Kish S. J., Morito C. L., Hornykiewicz O. Brain glutathione peroxidase in neurodegenerative disorders. Neurochem. Pathol. 4:1986;23-28.
124. Kitaguchi N., Takahashi Y., Tokushima Y., Shiojuiri S., Ito H. Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity. Nature. 331:1988;530-532.
125. Koh J., Yang L. L., Cotman C. W. β amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 533:1990;315-320.
126. Kosik, K. S. and Greenberg, S. M. (1994) Tau protein and Alzheimer disease. In: Alzheimer Disease, pp. 335-344. Eds R. D. Terry, R. Katzman and K. L. Bick. Raven Press, New York.
127. Kowall N. W., Beal M. F., Busciglio J., Duffy L. K., Yankner B. A. An in vivo model for the neurodegenerative effects of β amyloid and protection by substance P. Proc. natl Acad. Sci. U.S.A. 88:1991;7247-7251.
128. Kuiper G. G. J. M., Gustafsson J. A. The novel estrogen receptor-beta subtype-potential role in the cell- and promoter-specific actions of estrogens and antiestrogens. FEBS Lett. 410:1997;87-90.
129. Lamb B. T. Making models for Alzheimer's disease. Nat. Genet. 9:1995;4-6.
130. Lamb B. T., Sisodia S. S., Lawler A. M., Slunt H. H., Kitt C. A., Kearns W. G., Pearson P. L., Price D. L., Gearhart J. D. Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice. Nat. Genet. 5:1993;22-30.
131. Lansbury P. T., Costa P. R., Griffiths J. M., Simon E. J., Auger M., Halverson K. J., Kocisko D. A., Hendsch Z. S., Ashburn T. T., Spencer R. G. S., Tidor B., Griffin R. G. Structural model for the β amyloid fibril: interstrand alignment of an antiparallel β sheet comprising a C-terminal peptide. Nat. Struct. Biol. 2:1995;990-998.
132. Lemere C. A., Blusztajn J. K., Yamaguchi H., Wisniewski T., Saido T. C., Selkoe D. J. Sequence of deposition of heterogeneous amyloid β-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3:1996;16-32.
133. Levy-Lahad E. W., Wasco W., Poorka J.et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 269:1995;973-977.
134. LeWitt P. A. Neuroprotection by anti-oxidant strategies in Parkinson's disease. Eur. Neurol. 33:1993;24-30. S 1.
135. Lezoualc'h F., Behl C. Activation of the transcription factor NF-κB is a common signal induced by β-amyloid, amylin and hydrogen peroxide. Alzheimer's Res. 3:1997;43-50.
136. Lezoualc'h F., Behl C. Transcription factor NF-κB: friend or foe of neurons? Mol. Psychiat. 3:1998;15-20.
137. Lezoualc'h F., Skutella T., Widmann M., Behl C. Melatonin prevents oxidative stress-induced cell death in hippocampal cells. Neuroreport. 7:1996;2071-2077.
138. Lezoualc'h, F., Sagara, Y., Holsboer, F. and Behl, C. (1998) High constitutive NF-κB activity mediates resistance to oxidative stress in neuronal cells. J. Neurosci 18, 3224-3232.
139. Li Y. H., Maher P., Schubert D. A role for 12-lipooxygenase in nerve cell death caused by glutathione depletion. Neuron. 19:1997;453-463.
140. Lipton S. A. Janus faces of NF-kappa B: neurodestruction versus neuroprotection. Nat. Med. 3:1997;20-22.
141. Liu G. T., Zhang T. M., Wang B. E., Wang Y. W. Protective action of seven natural phenolic compounds against peroxidative damage to biomembranes. Biochem. Pharmac. 43:1992;147-152.
142. Lo A. C. Y., Haass C., Wagner S. L., Teplow D. B., Sisodia S. S. Metabolism of the "Swedish" amyloid precursor protein variant in Madin-Darby canine kidney cells. J. Biol. Chem. 269:1994;22099-22104.
143. Lohr J. B. Oxygen radicals and neuropsychiatric illness. Arch. Gen. Psychiat. 48:1991;1097-1106.
144. Lomakin A., Teplow D. B., Kirschner D. A., Benedek G. B. Kinetic theory of fibrillogenesis of amyloid beta-protein. Proc. natl Acad. Sci. U.S.A. 94:1997;7942-7947.
145. London J. A., Biegel D., Pachter J. S. Neurocytopathic effects of beta-amyloid-stimulated monocytes-a potential mechanism for central nervous system damage in Alzheimer disease. Proc. natl Acad. Sci. U.S.A. 93:1996;4147-4152.
146. Lorenzo A., Yankner B. A. Beta amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. natl Acad. Sci. U.S.A. 91:1994;12243-12247.
147. Lorenzo A., Razzaboni B., Weir C., Yankner B. A. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature. 368:1994;750-756.
148. Lovell M. A., Ehmann W. D., Butler S. M., Markesbery W. R. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology. 45:1995;1594-1601.
149. Lowenberg K., Waggoner R. Familial organic psychosis (Alzheimer's type). Arch. Neurol. Psychiat. 31:1934;737-754.
150. Mann D. M. A. The neuropathology of Alzheimer's disease: a review with pathogenetic, aetiological and therapeutic considerations. Mech. Ageing Dev. 31:1985;213-255.
151. Marcus D. L., Thomas C., Rodriguez C., Simberkoff K., Tsai J. S., Strafaci J. A., Freedman M. L. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp. Neurol. 150:1998;40-44.
152. Markesbery W. R. Oxidative stress in Alzheimer's disease. Free Rad. Biol. Med. 23:1997;134-147.
153. Marklund S. L., Adolfsson R., Gottfries C. G., Winblad B. Superoxide dismutase isoenzymes in normal brains and in brains from patients with dementia of Alzheimer type. J. Neurol. Sci. 67:1985;319-325.
154. Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. natl Acad. Sci. U.S.A. 82:1985;4245-4249.
155. Mattson M. P. Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivatives. Phys. Rev. 77:1997;1081-1132.
156. Mattson M. P., Goodman Y. Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res. 676:1995;219-224.
157. Mattson M. P., Cheng B., Davis D., Bryant K., Lieberburg I., Rydel R. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12:1992;376-389.
158. Mattson M. P., Tomaselli K. J., Rydel R. E. Calcium-destabilizing and neurodegenerative effects of aggregated β-amyloid peptide are attenuated by basic FGF. Brain Res. 621:1993;35-49.
159. 2+ homeostasis in Alzheimer's disease. TINS. 16:1993;409-414.
160. May P. C., Boggs L. N., Fuson K. S. Neurotoxicity of human amylin in rat primary hippocampal cultures: similarity to Alzheimer's disease amyloid-beta neurotoxicity. J. Neurochem. 61:1993;2330-2333.
161. Mayeux R., Saunders A. M., Shea S., Mirra S., Evans D., Roses A. D., Hyman B. T., Crain B., Tang M.-X., Phelps C. H. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N. Engl. J. Med. 338:1998;506-511.
162. McEwen B. S. Non-genomic and genomic effects of steroids on neural activity. Trends Pharmac. Sci. 12:1991;141-147.
163. McGeer P. L., McGeer E. G. The inflammatory response system of brain-implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. 21:1995;195-218.
164. McGeer E. G., McGeer P. L. The role of the immune system in neurodegenerative disorders. Movement Disord. 12:1996;855-858.
165. McGeer E. G., McGeer P. L. Inflammatory cytokines in the CNS - possible role in the pathogenesis of neurodegenerative disorders and therapeutic implications. CNS Drugs. 7:1997;214-228.
166. McGeer P. L., Schulzer M., McGeer E. G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease-a review of 17 epidemiologic studies. Neurology. 47:1996;425-432.
167. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadian E. M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 34:1984;939-944.
168. Mecocci P., MacGarvey U., Beal M. F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36:1994;747-750.
169. Meda L., Cassatella M. A., Szendrei G. I., Otvos L., Baron P., Villalba M., Ferrari D., Rossi F. Activation of microglial cells by β-amyloid protein and interferon-γ Nature. 347:1995;647-650.
170. Melhorn R. J., Cole G. The free radical theory of aging: a critical review. Adv. Free Radic. Biol. Med. 1:1985;165-223.
171. Miatto O., Gonzalez R. G., Buonanno F., Growdon J. H. In vitro 31p NMR spectroscopy detects altered phospholipid metabolism in Alzheimer's disease. Can. J. Neurol. Sci. 13:1986;535-539.
172. Mo J. Q., Hom D. G., Andersen J. K. Decrease in protective enzymes correlates with increased oxidative damage in the aging mouse brain. Mech. Aging Dev. 81:1995;73-82.
173. Mookjung I., Joo I., Sohn S., Kwon H. J., Huh K., Jung M. W. Estrogen blocks the neurotoxic effects of beta-amyloid (1-42) and induces neurite extension on B103 cells. Neurosci. Lett. 235:1997;101-104.
174. Moosmann B., Uhr M., Behl C. Neuroprotective potential of aromatic alcohols against oxidative cell death. FEBS Lett. 413:1997;467-472.
175. Moran P. M., Higgins L. S., Cordell B., Moser P. C. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human β-amyloid precursor protein. Proc. natl Acad. Sci. U.S.A. 92:1995;5341-5345.
176. Mucke L., Masliah E., Johnson W., Ruppe M., Alford M., Rockenstein E., Forss-Petter S., Pietropaolo M., Mallory M., Abraham C. Synaptotrophic effects of human amyloid β protein precursor in the cortex of transgenic mice. Brain Res. 666:1994;151-167.
177. Mudd L. M., Torres J., Lopez T. F., Montague J. Effects of growth factors and estrogen on the development of septal cholinergic neurons from the rat. Brain Res. Bull. 45:1998;137-142.
178. Muijsers R. B. M., Folkerts G., Henricks P. A., Sadeghihashjin G., Nijkamp F. P. Peroxynitrite-A two-faced metabolite of nitric oxide. Life Sci. 60:1997;1833-1845.
179. Mullan M., Crawford F. Genetic and molecular advances in Alzheimer's disease. Trends Neurosci. 16:1993;398-403.
180. Murrel J., Farlow M., Ghetti B., Benson M. D. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science. 254:1991;97-99.
181. Nakano M., Sugioka K., Naito I., Takehoshi S., Niki E. Novel and potent antioxidants on membrane phospholipid peroxidation: 2-hydroxy estrone and 2-hydroxy estradiol. Biochem. Biophys. Res. Commun. 142:1987;919-924.
182. Nishimoto I., Okamato T., Matsuura Y., Takahashi S., Oka Mato T., Murayama Y., Ogata E. Alzheimer amyloid protein precursor complexes with brain GTP-binding protein Go. Nature. 362:1993;75-79.
183. Nitsch R. M., Blusztajn J. K., Pittas A. G., Slack B. E., Growdon J. H., Wurtman R. J. Evidence for a membrane defect in Alzheimer disease brain. Proc. natl Acad. Sci. U.S.A. 89:1992;1671-1675.
184. Nitsch R. M., Slack B. E., Farber S. A., Schulz J. G., Deng M., Kim C., Borghesani P. R., Korver W., Wurtman R. J., Growdon J. H. Regulation of proteolytic processing of the amloid β-protein precursor of Alzheimer's disease in transfcetd cell lines and in brain slices. J. Neural. Transm. 44([Suppl.]):1994;21-27.
185. Ogawa S., Inoue S., Watanabe T., Hiroi H., Orimo A., Hosoi T., Ouchi Y., Muramatsu M. The complete primary structure of human estrogen receptor beta (hER-beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem. Biophys. Res. Commun. 243:1998;122-126.
186. Olanow C. W. A radical hypothesis for neurodegeneration. Trends Neurosci. 16:1993;439-444.
187. Paganini-Hill A., Henderson V. W. Estrogen deficiency and risk of Alzheimer's disease in women. Am. J. Epidemiol. 140:1994;256-261.
188. Pappolla M. A., Omar R. A., Kim K. S., Robakis N. K. Immun-histochemical evidence of antioxidant stress in Alzheimer's disease. Am. J. Pathol. 140:1992;621-628.
189. Parthasarathy S., Steinberg D., Witztum J. L. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. A. Rev. Med. 43:1992;219-225.
190. Parthasarathy S., Morales A. J., Murphy A. A. Antioxidant: a new role for RU486 and related compounds. J. Clin. Invest. 94:1994;1990-1995.
191. Paul S. M., Purdy R. H. Neuroactive steroids. FASEB J. 6:1992;2311-2322.
192. Pike C. J., Walencewicz A. J., Glabe C. G., Cotman C. W. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563:1991;311-314.
193. Pike C. J., Burdick D., Walencewicz A. J., Glabe C. G., Cotman C. W. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13:1993;1676-1687.
194. Podlisny M. B., Stephenson D. T., Frosch M. P., Tolan D. R., Lieberburg I., Clemens J. A., Selkoe D. J. Microinjection of synthetic amyloid β-protein in monkey cerebral cortex fails to produce acute neurotoxicity. Am. J. Pathol. 142:1993;17-24.
195. Ponte P., Gonzalez-Dewhitt P., Schilling J., Miller J., Hsu D., Greenberg B., Davis K., Wallace W., Lieberburg I., Fuller F. A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature. 331:1988;525-527.
196. Praprotnik D., Smith M. A., Richey P. L., Vinters H. V., Perry G. Plasma membrane fragility in dystrophic neurites in senile plaques of Alzheimer's disease: an index of oxidative stress. Acta Neuropathol. 91:1996;1-5.
197. Price D. L. New perspectives on Alzheimer's disease. A. Rev. Neurosci. 9:1986;489-512.
198. Prusiner S. B. Novel proteinaceous infectious particles cause scrapie. Science. 216:1982;136-144.
199. Prusiner S. B. Molecular biology and pathogenesis of prion diseases. Trends Biochem. Sci. 21:1996;482-487.
200. Quon D., Wang Y., Catalano R., Scardina J. M., Murakami K., Cordell B. Formation of β-amyloid protein deposits in brains of transgenic mice. Nature. 352:1991;239-241.
201. Reisberg, B., Ferris, S. H., DeLeon, M. J., Kluger, A., Franssen, E., Borenstein, J. and Alba, R. C. (1989) Progress in Clinical Biological Research, 367, 23-41.
202. Reiter R. J. Functional pleiotropy of the neurohormone melatonin: antioxidant protection and neuroendocrine regulation. Frontiers Neuroendocrinol. 16:1995;383-415.
203. Rich J. B., Rassmusson D. X., Folstein M. F., Carson K. A., Kawas C., Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 45:1995;51-55.
204. Rifici V. A., Khachadurian A. K. The inhibition of low-density lipoprotein oxidation by 17-β estradiol. Metabolism. 41:1992;1110-1114.
205. Rocca W. A., Hofman A., Brayne C., Breteler M. M., Clarke M., Copeland J. R., Dantigues J. F., Engedal K., Hagnell O., Heeren T. J. Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings. Ann. Neurol. 30:1991;381-390.
206. Rogers J., Cooper N. R., Webster S., Schultz J., McGeer P. L., Styren S. D., Civin W. H., Brachova L., Bradt B., Ward P., Lieberburg I. Complement activation by β-amyloid in Alzheimer disease. Proc. natl Acad. Sci. U.S.A. 89:1992;10016-10020.
207. Rogers J., Kirby L. C., Hempelman S. R., Berry D. L., McGeer P. L., Kaszniak A. W., Zalinski J., Cofield M., Mansukhani L., Willson P., Kogan F. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
208. Roher A. E., Ball M. J., Bhave S. V., Wakade A. R. β-Amyloid from Alzheimer's disease brain inhibits sprouting and survival of sympathetic neurons. Biochem. Biophys. Res. Commun. 174:1991;572-579.
209. Roses A. D. Apolipoprotein E, a gene with complex biological interactions in the aging brain. Neurobiol. Dis. 4:1997;170-185.
210. Rozemuller J. M., Eikelenboom P., Pals S. T., Stam F. C. Microglial cells around amyloid plaques in Alzheimer's disease express leukocyte adhesion molecules of the LFA-1 family. Neurosci. Lett. 101:1989;288-292.
211. Rupprecht R. The neuropsychophramacological potential of neuroactive steroids. J. Psychiatr. Res. 31:1997;297-314.
212. Sagara Y., Dargusch R., Klier F. G., Schubert D., Behl C. Increased antioxidant enzyme activity in amyloid β protein resistant cells. J. Neurosci. 16:1996;497-505.
213. Saitoh T., Sundsmo M., Roch J., Ximura M., Cole G., Schubert D., Oltersdorf T., Schenk D. Secreted from of amyloid β protein precursor is involved in the growth regulation of fibroblasts. Cell. 58:1989;615-622.
214. Sandbrink R., Hartmann T., Masters C. L., Beyreuther K. Genes contributing to Alzheimer's disease. Mol. Psychiat. 1:1996;27-40.
215. Sano M., Erneslo C., Thomas R. G., Klauber M. R., Schafer K., Grundman M., Woodbury P., Growdon J., Colman C. W., Pfeiffer W., Schneider L. S., Thal L. J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N. Engl. J. Med. 336:1997;1216-1222.
216. Saunders A. M., Strittmatter W. J., Schmechel D., St. George-Hyslop P. H., Pericak-Vance M. A., Joo S. H., Rosi B. L., Gusella J. F., Crapper-MacLachlan D. R., Al-Berts M. J., Hulette C., Crain B., Goldgaber D., Roses A. D. Association of apolipoprotein E allele ε4 with late onset familial and sporadic Alzheimer's disease. Neurology. 43:1993;1467-1472.
217. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T. D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., Younkin S. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. 2:1996;864-870.
218. Schreck R., Rieber P., Baeuerle P. A. Reactive oxygen intermediates are apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J. 10:1991;2247-2258.
219. Schubert, D. (1994) The Structure and Function of Alzheimer's Amyloid Beta Proteins. RG Landes Company, Austin.
220. Schubert D., Behl C. The expression of amyloid beta protein precursor protects nerve cells from β-amyloid and glutamate toxicity and alters their interaction with the extracellular matrix. Brain Res. 629:1993;275-282.
221. Schubert D., Jin L.-W., Saitoh T., Cole G. The regulation of amyloid β protein precursor secretion and its modulatory role in cell adhesion. Neuron. 3:1989;689-694.
222. Schubert D., Behl C., Lesley R., Brack A., Dargusch R., Sagara Y., Kimura H. Amyloid peptides are toxic via a common oxidative mechanism. Proc. natl Acad. Sci. U.S.A. 92:1995;1989-1993.
223. Schweers O., Mandelkow E. M., Biernat J., Mandelkow E. Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc. natl Acad. Sci. U.S.A. 92:1995;8463-8467.
224. Selkoe D. J. Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci. 16:1993;403-409.
225. Selkoe D. J. Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer's disease. A. Rev. Cell Biol. 10:1994;373-403.
226. Selkoe D. J. Amyloid beta-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 271:1996;18295-18298.
227. Sendtner M., Thoenen H. Oxidative stress and motoneuron disease. Curr. Biol. 4:1994;1036-1039.
228. Shearman M. S., Ragan C. I., Iversen L. L. Inhibition of PC12 cell redox activity is a specific early indicator of the mechanism of beta-amyloid-mediated cell death. Proc. natl Acad. Sci. U.S.A. 91:1994;1470-1474.
229. Sherrington R. E., Rogaev E. I., Liang Y., Rogaeva E. A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 375:1995;754-760.
230. Shoji M., Golde T. E., Ghiso J., Cheung T. T., Estus S., Shaffer L. M., Cai X.-D., McKay M., Tintner R., Frangione B., Younkin S. G. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science. 258:1992;126-129.
231. Sies H. Strategies of antioxidant defense. Eur. J. Biochem. 215:1993;213-219.
232. Simpkins J. W., Singh M., Bishop J. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiol. Aging. 15:1994;195-197. (S).
233. Singer T. P., Ramsay P. R. Monoamine oxidases: old friends hold many surprises. FASEB J. 9:1995;605-610.
234. Sisodia S. S. β-Amyloid precursor protein cleavage by a membrane-bound protease. Proc. natl Acad. Sci. U.S.A. 89:1992;6075-6079.
235. Sisodia S. S., Price D. L. role of the beta-amyloid protein in Alzheimer's disease. FASEB J. 9:1995;366-370.
236. Small D. H., Michaelson S., Sberna G. Non-classical actions of cholinesterases-role in cellular differentiation, tumorigenesis and Alzheimer's disease. Neurochem. Int. 28:1996;453-483.
237. Smith C. D., Carney J. M., Starke-Reed P. E., Oliver C. N., Stadtman E. R., Floyd R. A., Markesbery W. R. Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer disease. Proc. natl Acad. Sci. U.S.A. 88:1991;10540-10543.
238. Smith M. A., Kutty R. K., Richey P. L., Yan S. D., Stern D., Chader G. J., Wiggert B., Petersen R. B., Perry G. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am. J. Pathol. 145:1994;42-47.
239. Smith M. A., Siedlak S. L., Richey P. L., Mulvihill P., Ghiso I., Frangione B., Tagliavini F., Giaccone G., Bugiani O., Praprotnik D., Kalaria R. N., Perry G. Tau protein directly interacts with the amyloid beta-protein precursor-implications for Alzheimer's disease. Nature Med. 1:1995;365-369.
240. Smith M. A., Sayre L. M., Monnier V. M., Perry G. Radical aging in Alzheimer's disease. Trends Neurosci. 18:1995;172-176.
241. Smith M. A., Rudnicka-Nawrot M., Richey P. L., Praprotnik D., Mulvihill P., Miller C. A., Sayre L. M., Perry G. Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J. Neurochem. 64:1995;2660-2666.
242. Smith M. A., Perry G., Richey P. L., Sayre L. M., Anderson V. E., Beal M. F., Kowall N. Oxidative damage in Alzheimer's. Nature. 382:1996;120-121.
243. Snow A. D., Sekiguchi R., Nochlin D., Fraser P., Kimata K., Mizutani A., Arai M., Schreier W. A., Morgan D. G. An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar Aβ-amyloid in rat brain. Neuron. 12:1994;219-234.
244. Snow A. D., Kinsella M. G., Parks E., Sekiguchi R. T., Miller J. D., Kimata K., Wight T. N. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amylod protein of Alzheimer's disease. Arch. Biochem. Biophys. 320:1995;84-95.
245. St. George-Hyslop P. Genetic determinants of Alzheimer disease. Prog. Clin. Biol. Res. 393:1995;139-145.
246. Strauss S., Bauer J., Ganter U., Jonas U., Berger M., Volk B. Detection of interleukin-6 and α-2-macroglobulin immunorecativity in cortex and hippocampus of Alzheimer's disease patients. Lab. Invest. 66:1992;223-230.
247. Strittmatter W. J., Roses A. D. Apolipoprotein E and Alzheimer disease. Proc. natl Acad. Sci. U.S.A. 92:1995;4725-4727.
248. Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., Roses A. D. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. natl Acad. Sci. U.S.A. 90:1993;1977-1981.
249. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K. H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P. A., Waridel C., Calhoun M. E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. natl Acad. Sci. U.S.A. 94:1997;13287-13292.
250. Subbarao K. V., Richardson J. S., Ang L. C. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J. Neurochem. 55:1990;342-345.
251. Subbiah M. T. R., Kessel B., Agrawal M., Rajan R., Abplanalp W., Rymaszewski Z. Antioxidant potential of specific estrogens and lipid peroxidation. J. Clin. Endocrinol. Metab. 77:1993;1095-1097.
252. Sugioka K., Shimosegawa Y., Nakano M. Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEBS Lett. 210:1987;37-39.
253. 717) mutants. Science. 264:1994;1336-1340.
254. Tang M. X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., Andrews H., Mayeux R. Effect of oestrogen during menopause on risk and age of onset of Alzheimer's disease. Lancet. 348:1996;429-432.
255. Tanzi R. E., McClatchy A. I., Lamperti E. D., Villa-Kornaroff L., Gusella J. F., Neve R. L. Proease inhibitor domain encoded by an amyloid precursor mRNA associated with Alzheimer's disease. Nature. 331:1988;528-530.
256. Tanzi R. E., Kovacs D. M., Kim T.-W., Moir R. D., Guenette S. Y., Wasco W. The gene defects responsible for familial Alzheimers disease. Neurobiol. Dis. 3:1996;159-168.
257. Terry, R. D. (1985) Alzheimer's disease. In: Textbook of Neuropathology, pp. 824-841. Eds R. L. Davis and D. M. Robertson. Williams and Wilkins, Baltimore.
258. Terry R. D., Masliah E., Salmon D. P., Butters N., De Teresa R., Hill R., Hansen L. A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30:1991;572-580.
259. Terry, R. D., Katzmann, R. and Bick, K. L. (Eds) (1994) Alzheimer's Disease. Raven Press, New York.
260. Thal L. J. Potential prevention strategies for Alzheimer disease. Alz. Dis. Assoc. Dis. 10:1996;6-8.
261. Thoenen H. Neurotrophins and neuronal plasticity. Science. 270:1995;593-598.
262. Tocco G., Freiremoar J., Schreiber S. S., Sakhi S. H., Aisen P. S., Pasinetti G. M. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain-implications for Alzheimers-disease. Exp. Neurol. 144:1997;339-349.
263. Toran-Allerand C. D., Miranda R. C., Bentham W. D., Sohrabji F., Brown T. J., Hochberg R. B., MacLusky N. J. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc. natl Acad. Sci. U.S.A. 89:1992;4668-4672.
264. Trejo J., Massamiri T., Deng T., Dewji N. N., Bayney R. M., Brown J. H. A direct role for protein kinase C and the transcription factor Jun/AP-1 in the regulation of the Alzheimer's β-amyloid precursor protein gene. J. Biol. Chem. 269:1994;21682-21690.
265. Tremblay G. B., Tremblay A., Copeland N. G., Gilbert D. J., Jenkins N. A., Labrie F., Giguere V. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Molec. Endocrinol. 11:1997;353-365.
266. Tuszynski M. H., Sang H., Yoshida K., Gage F. H. Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann. Neurol. 30:1991;625-636.
267. Uchihara T., El Hachimi H. K., Duyckaerts C., Foncin J.-F., Fraser P. E., Levesque L., St. George-Hyslop P. H. Widespread immunoreactivity of presenilin in neurons of normal and Alzheimer's disease brains: double-labeling immunohistochemical study. Acta Neuropathol. 92:1996;325-330.
268. Van Nostrand W. E., Wagner S. L., Shankle W. R., Farrow J. S., Dick K. M., Rozemuller J. M., Kiper M. A., Wolters E. C., Zimmerman J., Cotman C. W., Cunninham D. D. Decreased levels of soluble amyloid β-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc. natl Acad. Sci. U.S.A. 89:1992;2551-2555.
269. Verbeek M. M., Otte-Höller I., Westphal J. R., Wesseling P., Ruiter D. J., de Waal R. M. W. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. Am. J. Pathol. 144:1994;104-116.
270. Verbeek M. M., Ruiter D. J., deWaal R. M. M. The role of amyloid in the pathogenesis of Alzheimer's disease. Biol. Chem. 378:1997;937-950.
271. Virchow R. Bau und Zusammensetzung der corpora amylacea des Menschen. Verh. Phys. Med. Ges. Würzburg. 2:1851;51-54.
272. Weaver C. E., Parkchung M., Gibbs T. T., Farb D. H. 17-Beta-estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors. Brain Res. 761:1997;338-341.
273. Webster S., O'Barr S., Rogers J. Enhanced aggregation and structure of amyloid β peptide after coincubation with C1q. J. Neurosci. Res. 39:1994;448-456.
274. Weidemann A., König G., Bunke D., Fischer P., Salbaum J. M., Masters C. L., Beyreuther K. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell. 57:1989;115-126.
275. Weyler W., Hsu Y. P. P., Breakefield X. O. Biochemistry and genetics of monoaminooxidase. Pharmac. Ther. 47:1990;391-417.
276. Whitehouse P. J., Price D. L., Struble R. G., Clark A. W., Coyle A. W., Delon M. R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 215:1982;1237-1239.
277. Winkler J., Thal L. J. Clinical potential of growth factors in neurological disorders. Cns Drugs. 2:1994;465-478.
278. Winkler J., Connor D. J., Frautschy S. A., Behl C., Waite J. J., Cole G. M., Thal L. J. Lack of long-term effects after β-amyloid protein injections in rat brain. Neurobiol. Aging. 15:1994;601-607.
279. Winkler J., Suhr S. T., Gage F. H., Thal L. J., Fisher L. J. Essential role of neocortical acetylcholinee in spatial memory. Nature. 375:1995;484-487.
280. Winkler J., Ramirez G. A., Kuhn H. G., Peterson D. A., Daylollini P. A., Stewart G. R., Tuszynski M. H., Gage F. H., Thal L. J. Reversible schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Ann. Neurol. 41:1997;82-93.
281. Wisniewski K. E., Wisniewski H. M., Wen G. Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 17:1985;278-282.
282. Wisniewski T., Ghiso J., Frangione B. Biology of Aβ amyloid in Alzheimer's disease. Neurobiol. Dis. 4:1997;313-328.
283. Wolozin B., Iwasaki K., Vito P., Ganjei J. K., Lacana E., Sunderland T., Zhao B. Y., Kusiak J. W., Wasco V., Dadamio L. Participation of presenilin 2 in apoptosis-enhanced basal activity conferred by an Alzheimer mutation. Science. 274:1996;1710-1713.
284. Yamaguchi H., Hirai S., Morimatsu M.et al. A variety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrated by β protein immunostaining. Acta Neuropathol. 76:1988;541-549.
285. Yan S. D., Chen X., Schmidt A.-M., Brett J., Godman G., Zou A. S., Scott C. W., Caputo C., Frappier T., Smith M. A., Perry G., Yen S. H., Stern D. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc. natl Acad. Sci. U.S.A. 91:1994;7787-7791.
286. Yan S. D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., Schmidt A. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature. 382:1996;685-691.
287. Yankner B. A. Mechanism of neuronal degeneration in Alzheimer's disease. Neuron. 16:1996;921-932.
288. Yankner B. A., Davies L. R., Fisher S., Villa-Komaroff L., Oster-Granite M. L., Neve R. L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science. 245:1989;417-420.
289. Yankner B. A., Duffy L., Kirschner D. Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science. 250:1990;279-282.
290. Yankner B. A., Caceres A., Duffy L. K. Nerve growth factor potentiates the neurotoxicity of β-amyloid. Proc. natl Acad. Sci. U.S.A. 87:1990;9020-9023.
291. Yoshikawa K., Aizawa T., Hayashi Y. Degeneration in vitro of post-mitotic neurons overexpressing the Alzheimer amyloid protein precursor. Nature. 359:1992;64-66.
292. Zhao W., Richardson J. S., Mombourquette M. J., Weil J. A. An in vitro EPR study of the free radical scavenging actions of the lazaroid antioxidants U-74500A and U-7851F. Free Radic. Biol. Med. 19:1995;21-30.
293. Zhou Y., Gopalakrishnan V., Richardson J. S. Actions of neurotoxic beta-amyloid on calcium homeostasis and viability of PC12 cells are blocked by antioxidants but not by calcium channel antagonists. J. Neurochem. 67:1996;1419-1425.